OBJECTIVE： To evaluate the pharmacoeconomics of pantoprazole vs. ranitidine in the treatment of gastricesophagitis reflux disease（GERD）. METHODS： Retrieved from PubMed， EMBase， The Cochrane Library， CNKI， VIP and Wanfang database， RCTs about pantoprazole vs. ranitidine in the treatment of GERD were selected until Sept. 2014. Two reviewers independently screened literature in accordance with the inclusion and exclusion criteria， and extracted the data of included studies. Stata 12.0 software was used to estimate therapeutic efficacy index and cost， and cost-effectiveness analysis was performed with the decision tree model. RESULTS： A total of 7 RCTs were included， involving 1 389 patients. Cost-effectiveness analysis showed that for gradeⅠ-Ⅲ （by Savary-Miller standard） GERD， cost-effectiveness ratios of ranitidine were all lower than those of pantoprazole （gradeⅠ： 18.86 vs. 57.93；gradeⅡor Ⅲ： 35.58 vs. 146.13）； gradeⅠ，Ⅱ，Ⅲ incremental cost-effectiveness ratio （ICER） were 335.53，349.85，349.85. Sensitivity analysis supported this conclusion. CONCLUSIONS： Ranitidine is more economic therapy plan for gradeⅠ-Ⅲ GERD， but its ICER fluctuates greatly. Individual therapy plan should be formulated according to disease condition and economic condition.